Analyst Price Target is $36.00
▲ +246.15% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $36.00, with a high forecast of $54.00 and a low forecast of $18.00. The average price target represents a 246.15% upside from the last price of $10.40.
Current Consensus is
Moderate Buy
The current consensus among 3 investment analysts is to moderate buy stock in Instil Bio. This Moderate Buy consensus rating has held steady for over two years.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Read More